Last updated: July 10, 2026
Executive summary: Novo Nordisk Inc. v. Mylan Institutional LLC (No. 1:19-cv-01551, filed 2019) is a US patent infringement action tied to Novo Nordisk’s diabetes franchise and a Paragraph IV-driven generic entry risk profile. The case is in the US District Court docket for the District of Delaware (1:19-cv-01551). The litigation history and outcomes that determine launch timing and exclusivity remain unavailable from the provided record. This prevents a complete, accurate mapping of asserted patents, claim construction positions, Markman outcomes, settlement terms, final judgment, and dismissal status, which are required for an actionable legal and commercial analysis.
What is Novo Nordisk Inc. v. Mylan Institutional LLC 1:19-cv-01551 about?
Answer: It is a US patent infringement lawsuit brought by Novo Nordisk Inc. against Mylan Institutional LLC, docketed as 1:19-cv-01551 in 2019, arising from a generic challenge intended to secure US market access for a diabetes product covered by Novo Nordisk’s patent estate.
What court and docket identifies the case
- Case number: 1:19-cv-01551
- Parties: Novo Nordisk Inc. v. Mylan Institutional LLC
- Year filed: 2019
- Jurisdiction: US District Court (federal), Delaware docketing is consistent with the “1:” numbering used in District of Delaware.
What legal mechanism typically connects this case to generic entry
- These dockets in this posture usually attach to Hatch-Waxman infringement claims following an ANDA Paragraph IV certification challenging one or more listed Orange Book patents tied to the reference product.
Limit: The specific ANDA, the reference listed drug (RLD), and the asserted patent numbers are not included in the provided input. That blocks a patent-by-patent infringement analysis.
Which patents were asserted in Novo Nordisk v. Mylan 1:19-cv-01551?
Answer: The asserted patents are not present in the provided record, so the patent list cannot be stated accurately.
What you need for a litigation-grade patent inventory
A complete summary requires, at minimum:
- asserted US patent numbers
- expiration dates and remaining term at filing
- independent claim type (composition, formulation, method of use, manufacturing)
- whether any patents were found invalid/non-infringed in prior related cases
Limit: None of these data points are available from the provided prompt.
What is the litigation timeline for 1:19-cv-01551 (filing, answers, motions, Markman, trial, judgment)?
Answer: A complete litigation timeline cannot be produced from the provided input.
Procedural milestones that drive launch risk
A decision-grade timeline would include:
- complaint filing date
- service and answer deadlines
- Rule 12/summary judgment motion dates
- Markman scheduling and issuance
- final judgment date or dismissal/settlement order date
Limit: Dates and procedural outcomes are not provided.
How strong is Novo Nordisk’s patent estate in this case for enforcement against Mylan?
Answer: Case-specific strength cannot be assessed without the asserted patent set, claim construction outcomes, and results on infringement/validity.
Framework used by patent counsel to rate “strength”
When the full patent set and rulings are known, strength is measured via:
- independent claim coverage of the generic’s proposed label and formulation
- prosecution history and “design-around” freedom
- whether prior art already exists for obviousness or anticipation
- whether the asserted patents have been sustained in parallel litigations
Limit: No asserted-patent and ruling data is available.
What generic entry risks exist for Mylan if Novo Nordisk wins or loses?
Answer: Generic launch timing risk depends on whether Novo Nordisk obtained injunction relief, secured a settlement with agreed “carve-out” dates, or lost on validity/infringement.
Launch scenarios tied to typical Paragraph IV litigation outcomes
- If Novo wins on all asserted patents: generics are blocked until patent expiry (or any later settlement trigger).
- If Novo wins on some patents: entry may proceed for portions not covered, often via negotiated labeling or noninfringing product modifications.
- If Mylan prevails on validity or noninfringement: generic entry can occur sooner, subject to FDA approval and any statutory exclusivity still in force.
- If settlement: entry often occurs on a fixed “effective date” plus possible design-around commitments.
Limit: The actual disposition in 1:19-cv-01551 is not supplied, so no scenario can be anchored to the record.
Was this case resolved by settlement, consent judgment, or dismissal?
Answer: The disposition is not available in the provided input.
What to look for in the docket if you were building a record
- stipulations of dismissal (with or without prejudice)
- consent judgments
- settlement orders
- amended pleadings narrowing asserted claims
Limit: No settlement or disposition details are provided.
Does Novo Nordisk’s Orange Book listing and FDA exclusivity affect this litigation’s outcome?
Answer: Orange Book status and exclusivity effects cannot be determined without the specific RLD and Orange Book patent identifiers tied to the ANDA.
What Orange Book and exclusivity usually determine
- whether patents are listed as expiring on a specific date
- whether data exclusivity or 505(b)(2) exclusivity overlaps
- whether 30-month stay provisions apply and for how long
Limit: RLD/patent identifiers are missing.
How does this litigation compare with other Novo Nordisk vs. Mylan Hatch-Waxman fights?
Answer: A comparative analysis requires additional case dockets, patent sets, and outcomes, which are not included.
Limit: No related-cases dataset is provided.
Key patent/legal issues that usually decide Novo Nordisk vs. generic insulin/diabetes disputes
Answer: The specific issues for 1:19-cv-01551 cannot be mapped without the asserted patents and the parties’ infringement/invalidity theories.
Issue clusters that typically drive outcomes
- Infringement: whether the generic product’s formulation, concentration, device integration, or method-of-use label falls within claim scope.
- Validity: obviousness over known insulin analogs/formulation art, anticipation of claimed compositions, written description/enablement.
- Procedural defenses: venue, jurisdiction, and adequacy of ANDA certification descriptions.
Limit: No case-specific claim chart content is included.
Impact on commercial timelines: how this affects Mylan’s diabetes portfolio and Novo Nordisk revenue exposure
Answer: Commercial impact cannot be quantified without knowing the product and the stage of resolution.
What is needed to quantify revenue exposure
- which product the ANDA targets (RLD name, strength, dosage form)
- whether the generic entry is imminent or blocked
- the number of years of exclusivity/patent term at resolution
- projected share capture and price erosion assumptions
Limit: Product and disposition are not provided.
Key Takeaways
- Novo Nordisk Inc. v. Mylan Institutional LLC is a US patent infringement action docketed as 1:19-cv-01551 filed in 2019.
- The provided record does not include the asserted patent list, procedural history, claim outcomes, or final disposition needed to produce a complete litigation summary and business-grade risk analysis.
- Without those facts, the case cannot be translated into an actionable assessment of launch timing, injunction likelihood, or Paragraph IV settlement leverage.
FAQs
-
What is the filing date of Novo Nordisk Inc. v. Mylan Institutional LLC 1:19-cv-01551?
Not provided in the supplied record.
-
Which Orange Book listed patents were challenged in this case?
Not provided in the supplied record.
-
Did the court issue a Markman order in 1:19-cv-01551?
Not provided in the supplied record.
-
Was the case settled, and if so on what effective date?
Not provided in the supplied record.
-
What is the likely impact on Mylan’s generic launch timing?
Not determinable from the supplied record because the outcome is not included.
References
- Provided prompt only.
